Alder BioPharmaceuticals Inc. (NASDAQ:ALDR)‘s stock had its “buy” rating restated by equities researchers at Jefferies Group in a report issued on Sunday. They currently have a $57.00 price objective on the biopharmaceutical company’s stock. Jefferies Group’s target price points to a potential upside of 98.26% from the stock’s previous close.

ALDR has been the subject of several other reports. Zacks Investment Research lowered shares of Alder BioPharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, October 13th. Aegis began coverage on shares of Alder BioPharmaceuticals in a research note on Monday, November 7th. They issued a “buy” rating and a $41.00 price target for the company. Piper Jaffray Cos. began coverage on shares of Alder BioPharmaceuticals in a research note on Monday, October 31st. They issued an “overweight” rating and a $47.00 price target for the company. Brean Capital began coverage on shares of Alder BioPharmaceuticals in a research note on Friday, September 30th. They issued a “buy” rating and a $45.00 price target for the company. Finally, JPMorgan Chase & Co. began coverage on shares of Alder BioPharmaceuticals in a research note on Tuesday, September 13th. They issued an “overweight” rating and a $40.00 price target for the company. Ten analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and an average target price of $43.63.

Analyst Recommendations for Alder BioPharmaceuticals (NASDAQ:ALDR)

Shares of Alder BioPharmaceuticals (NASDAQ:ALDR) opened at 28.75 on Friday. Alder BioPharmaceuticals has a 52-week low of $15.82 and a 52-week high of $39.43. The company’s market capitalization is $1.45 billion. The stock’s 50 day moving average is $28.69 and its 200 day moving average is $29.02.

Alder BioPharmaceuticals (NASDAQ:ALDR) last posted its earnings results on Thursday, October 27th. The biopharmaceutical company reported ($0.70) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.85) by $0.15. During the same quarter in the previous year, the firm earned ($0.62) earnings per share. Equities analysts expect that Alder BioPharmaceuticals will post ($3.13) EPS for the current year.

In related news, CEO Randall C. Schatzman sold 8,181 shares of the business’s stock in a transaction on Monday, October 3rd. The shares were sold at an average price of $31.15, for a total value of $254,838.15. Following the sale, the chief executive officer now owns 122,949 shares in the company, valued at $3,829,861.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Jeffrey T. L. Smith sold 3,000 shares of the business’s stock in a transaction on Thursday, September 1st. The stock was sold at an average price of $32.49, for a total transaction of $97,470.00. Following the completion of the sale, the vice president now owns 3,000 shares in the company, valued at approximately $97,470. The disclosure for this sale can be found here. 11.50% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD bought a new stake in shares of Alder BioPharmaceuticals during the third quarter worth about $9,518,000. Cornerstone Capital Management Holdings LLC. raised its stake in shares of Alder BioPharmaceuticals by 88.7% in the third quarter. Cornerstone Capital Management Holdings LLC. now owns 5,662 shares of the biopharmaceutical company’s stock worth $185,000 after buying an additional 2,662 shares in the last quarter. Credit Suisse AG raised its stake in shares of Alder BioPharmaceuticals by 8.5% in the third quarter. Credit Suisse AG now owns 202,839 shares of the biopharmaceutical company’s stock worth $6,648,000 after buying an additional 15,927 shares in the last quarter. Pioneer Investment Management Inc. raised its stake in shares of Alder BioPharmaceuticals by 13.4% in the third quarter. Pioneer Investment Management Inc. now owns 935,441 shares of the biopharmaceutical company’s stock worth $30,654,000 after buying an additional 110,453 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. bought a new stake in shares of Alder BioPharmaceuticals during the third quarter worth about $1,311,000.

Alder BioPharmaceuticals Company Profile

Alder Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response.

5 Day Chart for NASDAQ:ALDR

Receive News & Stock Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related stocks with our FREE daily email newsletter.